Sinovac Biotech Ltd.
No.39 Shangdi Xi Rd
Haidian District
Beijing
100085
China
Tel: 86-10-82890088
Fax: 86-10-62966910
Website: http://www.sinovac.com/
Email: sinovac@sinovac.com
422 articles about Sinovac Biotech Ltd.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
-
Sinovac Amends Shareholder Rights Plan
2/21/2020
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its board of directors has amended its shareholder rights plan.
-
BioSpace Global Roundup, Jan. 2
1/2/2020
Companies from across the globe announce updates to their business and pipeline. -
Sinovac Announces Approval of Varicella Vaccine for Prevention of Varicella-Zoster Virus (Chickenpox) in Children
12/27/2019
Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has approved and issued a Product license for the Company’s varicella vaccine to prevent the varicella-zoster virus in children from 1 to 12 years old.
-
Sinovac Reports Unaudited Third Quarter 2019 Financial Results
11/15/2019
Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the third quarter ended September 30, 2019.
-
Sinovac Reports Unaudited Second Quarter 2019 Financial Results
8/15/2019
Unaudited financial results for the second quarter ended June 30, 2019.
-
Sinovac Reports Unaudited First Quarter 2019 Financial Results
7/10/2019
Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the first quarter ended March 31, 2019.
-
Sinovac Reports Unaudited Second Half of 2018 Financial Results and Files 2018 Annual Report on Form 20-F
4/29/2019
Sinovac Biotech Ltd.Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has filed its 2018 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2018.
-
Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease
4/16/2019
The Sinovac-developed sIPV demonstrates both long-term affordability and accessibility and has the potential to contribute significantly to polio eradication in developing countries and the progress towards a polio-free world.
-
Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares - April 12, 2019
4/12/2019
Sinovac Biotech Ltd. provided an update for shareholders with regards to the exchange of preferred share purchase rights for the Company’s Common Shares and Series B Convertible Preferred Shares, originally announced on February 22, 2019, by press release.
-
Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares
3/8/2019
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, issued an update on the Exchange of Rights for Common and Series B Preferred Shares announced February 22, 2019.
-
Sinovac Determines Trigger Event Occurred Under Rights Agreement
2/22/2019
Board of Directors Amends and Restates Rights Agreement and Declares Dividend Distribution of New Preferred Share Purchase Rights.
-
Sinovac Comments on Antigua and Barbuda Court Decision Denying 1Globe Capital’s Claim; Current Board Was Validly Elected at Annual General Meeting
12/19/2018
Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the High Court of Justice of Antigua and Barbuda rejected the claim of 1Globe Capital LLC (“1Globe”) for a declaration that an alternative slate of directors had been elected at the Company’s Annual General Meeting in February 2018
-
Hong Kong High Court Issues Declaratory Orders and Permanent Injunctive Relief in Favor of Sinovac’s Biotech Ltd. Senior Management
11/28/2018
Permanent Injunction Restrains Mr. Li and Mr. Cao from Purporting to Act as or Take Any Actions as Directors of Sinovac HK or its subsidiaries
-
Sinovac Reports Unaudited First Half of 2018 Financial Results
11/8/2018
Sinovac Biotech Ltd. announced today its unaudited financial results for the six months ended June 30, 2018.
-
Sinovac Granted Interim Injunctive Relief Regarding Filings Bearing a Falsified Company Seal and Forged Board Member Signatures
10/22/2018
Senior management of Sinovac Biotech Ltd. and the lawful directors of Sinovac Hong Kong (“Lawful Directors”), Mr. Yin Weidong and Ms. Wang Nan, have been granted interim injunctive relief against Mr. Li Pengfei (“Mr. Li”) and Mr. Cao Jianzeng (“Mr. Cao”) by the High Court of the Hong Kong Special Administrative Region
-
U.S. District Court in Massachusetts Denies 1Globe's Motion for Preliminary Injunction to Enjoin Sinovac's Issuance of Shares
10/17/2018
Sinovac Biotech Ltd. today announced that the United States District Court of the District of Massachusetts denied 1Globe Capital LLC's ("1Globe") August 2018 motion for a preliminary injunction seeking to enjoin Sinovac from issuing shares of Company stock to the PIPE investors or any other individuals pending the outcome of the ongoing litigation between the parties in the High Court of Justice in Antigua and Barbuda.
-
Sinovac Comments on Unauthorized Use of Falsified Sinovac Hong Kong’s Company Seal and Subsidiary Board Member Signatures
10/10/2018
Sinovac Biotech Ltd. became aware Monday October 8, 2018 that unauthorized changes have been made to the Hong Kong Companies Registry for Sinovac Biotech (Hong Kong) Limited (“Sinovac HK”) and that unauthorized changes have been made to the Industry and Commerce Bureau of Beijing for Sinovac Biotech Co., Ltd.
-
DOJ Closes Investigation of Sinovac
9/17/2018
Sinovac Biotech Ltd. today announced that the U.S. Department of Justice ("DOJ") has closed its investigation, with no charges, into possible violations of the Foreign Corrupt Practices Act related to allegations that certain Sinovac employees made improper payments to Chinese government officials.